Effects of Rosemary Essential Oil on Human Cognition (Rosmarinus)
28 avril 2026 mis à jour par: Heloisa de Freitas Pacífico, Federal University of Paraíba
The Use of Rosmarinus Officinalis L. Essential Oil (Camphor and Cineol Chemotypes) in Cognition: a Randomized, Double-blind, Placebo-controlled Study
Aromatherapy is one of the complementary therapies that is carried out through essential oils.
The essential oil of Rosmarinus Officinalis L. (rosemary) has been gaining attention in aromatherapy research, as studies have shown that the use of this oil is one of the promising non-pharmacological therapies for cognition.
In this way, inhalation of rosemary essential oil is one of the forms of cognitive intervention across different age groups.
The study will aim to analyze the effect of rosemary essential oil, with the following chemotypes: camphor and cineole, on the cognitive performance of adults.
Significant differences are expected between the control (placebo) and experimental groups, given that studies in humans have already shown significant effects of rosemary essential oil on cognition.
Considering the inclusion and exclusion criteria of the study, participants will be allocated to either the control or experimental group.
Consequently, the application of the tests will be carried out neuropsychological tests for the pre-test evaluation, followed by aromatherapy (acute phase) and the reapplication of the tests (post-test phase 1).
For 14 days, the participants will chronically use rosemary essential oil and at the end they will participate in the reapplication of the neuropsychological tests (post-test phase 2).
For inferential analyses, the ANOVA test or its non-parametric equivalent will be used.
In addition, linear regressions may be performed to verify how much the essential oil can predict the outcome of the study's dependent variables.
Effect Size will also be calculated.
Keywords: Chronic intervention; neuropsychology; aromatherapy.
Aperçu de l'étude
Statut
Actif, ne recrute pas
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
63
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Paraíba
-
João Pessoa, Paraíba, Brésil, 58062-106
- Helô
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
Oui
La description
Inclusion Criteria:
- 1a Healthy adults
- 1b should be able to inhale the essential oil
Exclusion Criteria:
- 2a Neurodegenerative diseases
- 2b Traumatic brain injury
- 2c Brain tumors
- 2d Multiple sclerosis
- 2e Epileptic seizures
- 2f Anxiety Disorder
- 2g Depressive Disorders,
- 2h Uncontrolled arterial hypertension,
- 2i nutritional deficiency or thyroid disease.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: essential oil of Rosmarinus officinalis 1
Inhalation of 2 drops of rosemary camphor essential oil for 5 minutes, once a day for 1 week consecutive on a cotton pad followed
|
oil essential
|
|
Aucune intervention: Placebo
Inhalation of 2 drops of sunflower essential oil for 5 minutes, once a day for 1 week consecutive on a cotton pad followed
|
|
|
Comparateur actif: essential oil of Rosmarinus officinalis 2
Inhalation of 2 drops of rosemary cineol essential oil for 5 minutes, for once a day for 1 week consecutive on a cotton pad followed
|
oil essential
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
STROOP TEST
Délai: Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
Unit of measurement: time (seconds)
|
Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Subteste Digits of the Test WAIS-III - (Wechsler Adult Scale)
Délai: Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1a. Maximum raw score: 30 1b. Minimum raw score: 2 |
Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Subtest Number and Letter Sequence of the WAIS-III Test - (Wechsler Adult Scale)
Délai: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 21 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Tower of London
Délai: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 46 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Token Test
Délai: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 36 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Corsi Blocks
Délai: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 30 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Hopkins Verbal Learning
Délai: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 0 1b. Minimum raw score: 36 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
1 mars 2025
Achèvement primaire (Estimé)
1 décembre 2026
Achèvement de l'étude (Estimé)
31 décembre 2026
Dates d'inscription aux études
Première soumission
13 avril 2026
Première soumission répondant aux critères de contrôle qualité
28 avril 2026
Première publication (Réel)
1 mai 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
1 mai 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
28 avril 2026
Dernière vérification
1 avril 2026
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 80434324.0.0000.5188
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .